This article was downloaded by: [University of California Santa Barbara] On: 17 October 2014, At: 23:40 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn20

INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE: PROBES FOR ANTIVIRAL DRUG DISCOVERY

Sherry Story^a, Mukta Gupta^a, Eric Bonsu^a & Vasu Nair^a

^a Department of Pharmaceutical and Biomedical Sciences, The University of Georgia, Athens, Georgia, USA Published online: 15 Nov 2011.

To cite this article: Sherry Story, Mukta Gupta, Eric Bonsu & Vasu Nair (2005) INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE: PROBES FOR ANTIVIRAL DRUG DISCOVERY, Nucleosides, Nucleotides and Nucleic Acids, 24:5-7, 717-720, DOI: 10.1081/NCN-200060308

To link to this article: <u>http://dx.doi.org/10.1081/NCN-200060308</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions



INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE: PROBES FOR ANTIVIRAL DRUG DISCOVERY

Sherry Story, Mukta Gupta, Eric Bonsu, and Vasu Nair Department of Pharmaceutical and Biomedical Sciences, The University of Georgia, Athens, Georgia, 30602, USA

• The role of inosine monophosphate dehydrogenase (IMPDH) at the metabolic branch point of de novo purine nucleotide biosynthesis makes this enzyme an attractive probe for the discovery of antiviral compounds. Introduction of unsaturation at the 2-position of IMP, the natural substrate for IMPDH, produces Michael acceptors at that position, which results in these compounds being inhibitors of IMPDH. Consistent with this mechanism-based molecular design, some of the parent nucleosides exhibited antiviral activity.

Keywords IMPDH, Michael Acceptor, Antiviral Activity

INTRODUCTION

Inosine monophosphate dehydrogenase (IMPDH; EC 1.1.1.205) catalyzes the oxidation of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP) with the involvement of the coenzyme, nicotinamide adenine dinucleotide (NAD^+) , which is reduced to NADH.^[1,2] The role of IMPDH at this metabolic branch point of de novo purine nucleotide biosynthesis renders it a target for the discovery of antiviral, anticancer, and immunosuppressive agents.^[3] Consistent with this is the observation that some inhibitors of IMPDH have been found to have anticancer, antiviral, and immunosuppressive activity.^[4-6] IMPDH is a sulfhydryl enzyme in which the active-site Cys-331 residue may act as a nucleophilic participant in interactions with inhibitors that are Michael acceptors.^[7] This is also consistent with the mechanism of substrate action of IMPDH, which involves interaction of the enzyme and coenzyme (NAD⁺) complex at the 2-position of

Received 1 October 2004, accepted 21 January 2005.

Downloaded by [University of California Santa Barbara] at 23:40 17 October 2014

This project was supported by Grant No. AI056540 from the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We thank Drs. E. Kern and R. Sidwell for the antiviral screening data and Dr. D. Jung for technical assistance with the molecular modeling representation. Address correspondence to Vasu Nair, Department of Pharmaceutical and Biomedical Sciences, Room 320,

R. C. Wilson PH, The University of Georgia, Athens, GA 30602, USA; E-mail: vnair@rx.uga.edu

S. Story et al.



SCHEME 1 Example of the synthesis of a 2-substituted IMP analog.

IMP.^[1] X-ray crystallographic data support the suggestion of a covalent adduct formation between Cys-331 of IMPDH and IMP during catalysis.^[8] In an ongoing drug discovery program on antiviral compounds in our laboratory, we have utilized IMPDH as a probe for the initial identification of potential antiviral molecules.

RESULTS AND DISCUSSION

Modification of the 2-position of IMP involving Michael acceptors was key in the design of IMPDH inhibitors. Synthesis of the 2-substituted IMP analogs used both chemical and enzymatic methodologies. An example of the synthesis is shown in Scheme 1.^[9] The key steps that were involved included a palladium-catalyzed cross-coupling reaction, a modified Wittig reaction and a hydrolytic elimination reaction with the enzyme adenosine deaminase.^[10–12] For IMPDH studies, 5'phosphorylated compounds were needed and these were synthesized by standard phosphorylation methods.

The IMPDH used in this study was isolated from *E. coli* B3 strain on our laboratory.^[7] A comparison of the kinetic parameters of this IMPDH with others is shown in Table 1. IMPDH activity was measured by UV spectral methods by monitoring the formation of NADH at 340 nm. In inhibition studies, the inhibition reaction was initiated by the addition of various concentrations of inhibitor to the appropriate enzyme solution.^[7,13]

Enzyme	$V(s^{-1})$	IMP (Km) µM	NAD ⁺ (Km) µM
Human (Type I) ^a	1.8	14.2	42
Human (Type I) a	1.4	9.2	32
E. coli $(B3)^{\tilde{b}}$	6.0	12.0	315
Trichomonas foetus ^c	1.9	1.7	150

TABLE 1 Kinetic Parameters of Various IMPDHs

 $V(s^{-1})$ is turnover number per second.

^aBiochem. Pharmacol **1995**, 49, 1323-1329.

^bNair lab data.

^cBiochemistry 1999, 38, 15388-15397.

2-[2-(*Z*)-Fluorovinyl]inosine 5'-monophosphate (2-FVIMP) gave k_{inact} and K_i of 0.0269 s⁻¹ and 1.11 µM, respectively, whereas the well-known IMPDH inhibitor, 6-chloropurine ribonucleoside monophosphate gave values of 0.076 min⁻¹ and 62.0 µM. The inactivation of IMPDH by 2-FVIMP is time dependent and follows a two-step mechanism. Another 2-substituted nucleoside monophosphate, 6-chloro-2-ethynylpurine riboside monophosphate, was also a strong inhibitor of IMPDH with values of k_{inact} and K_i of 0.75 min⁻¹ and 4.25 µM, respectively. The mechanism of inhibition is similar to FVIMP (Figure 1). Comparisons were made with another inhibitor of IMPDH, 4-carboxamido-5-hydroxyimidazole riboside monophosphate, which exhibited a K_i of 0.5 nM.^[14]

Antiviral studies of the parent nucleosides of these inhibitors of IMPDH showed that 6-chloro-2-ethynylpurine riboside was active but toxic against the vaccinia virus (HFF cells, $IC_{50} > 0.8 \ \mu g/mL$; $CC_{50} \ 3.0 \ \mu g/mL$). Both 2-fluoro-vinylinosine and its 6-chloropurine analog also exhibited activity towards the vaccinia virus (SI < 4.5 and < 3.7). 4-Carboxamido-5-hydroxy-imidazole riboside



FIGURE 1 Representation of the interaction of FVIMP with IMPDH.

showed good activity against HSV-2 (HFF cells, $IC_{50} 0.26 \ \mu g/mL$; $CC_{50} > 100 \ \mu g/mL$) and VZV (HFF cells, $IC_{50} 2.8 \ \mu g/mL$; $CC_{50} > 100 \ \mu g/mL$). Other examples of the use of IMPDH as a probe for antiviral drug discovery are in progress.

REFERENCES

- Hedstrom, L. IMP dehydrogenase: mechanism of action and inhibition. Curr. Med. Chem. 1999, 6, 545– 560.
- Goldstein, B.M.; Colby, T.D. IMP dehydrogenase: structural aspects of inhibitor binding. Curr. Med. Chem. 1999, 6, 519–536.
- 3. De Clerq, E. Strategics in the design of antiviral drugs. Nat. Rev., Drug Discov. 2002, 11, 13-25.
- Franchetti, P.; Grifantini, M. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr. Med. Chem. 1999, 6, 599–614.
- Wang, W.; Papov, V.V.; Minakawa, N.; Matsuda, A.; Biemann, K.; Hedstrom, L. Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate. Biochemistry 1996, 35, 95–101.
- Nair, V.; Ussery, M.A. New hypoxanthine nucleosides with RNA antiviral activity. Antivir. Res. 1992, 19, 173–178.
- Pal, S.; Bera, B.; Nair, V. Inhibition of inosine monophosphate dehydrogenase (IMPDH) by the antiviral compound, 2-vinylinosine. Bioorg. Med. Chem. 2002, 10, 3615–3618.
- Colby, T.D.; Vanderveen, K.; Strickler, M.D.; Markham, G.D.; Goldstein, B.M. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc. Natl. Acad. Sci. U. S. A. 1999, *96*, 3531–3536.
- Nair, V.; Bera, B.; Kern, E.R. Synthesis and antiviral activities of 2-functionalized purine ribonucleosides. Nucleosides Nucleotides Nucleic Acids 2003, 22, 115–127.
- Nair, V.; Turner, G.A.; Buenger, G.S.; Chamberlain, S.D. New methodologies for the synthesis of C-2 functionalized hypoxanthine nucleosides. J. Org. Chem. 1988, 53, 3051-3057.
- 11. Nair, V.; Turner, G.A.; Chamberlain, S.D. Novel approaches to functionalized nucleosides via palladiumcatalyzed cross-coupling with organostannanes. J. Am. Chem. Soc. **1987**, *109*, 7223–7224.
- 12. Nair, V.; Sells, T.B. Enzymatic synthesis of 2',3'-dideoxyguanosine. Synlett 1991, 753-754.
- Nair, V.; Kamboj, R.C. Inhibition of inosine monophosphate dehydrogenase (IMPDH) by 2-[2-(Z)-fluorovinyl] inosine 5'-monophosphate. Bioorg. Med. Chem. Lett. 2003, 13, 645–647.
- Kerr, K.M.; Hedstrom, L. The roles of conserved carboxylate residues in IMP dehydrogenase and identification of a transition state analog. Biochemistry 1997, 36, 13365–13373.